AbbVie’s First Quarter 2026 Financial Results were officially released today, showcasing a robust start to the year for the pharmaceutical giant. The company reported a significant increase in net revenues, driven by the exceptional performance of its immunology and neuroscience portfolios. With a 12.4% increase in reported revenue, AbbVie continues to demonstrate its ability to navigate the post-exclusivity landscape of its former blockbuster, Humira.
Financial Highlights of the AbbVie First Quarter 2026 Financial Results
AbbVie delivered first-quarter net revenues of $15.002 billion, representing a 12.4% increase on a reported basis. Adjusted diluted earnings per share (EPS) reached $2.65, an increase of 7.7% compared to the same period last year. These results reflect the company’s strategic focus on its growth platform, which is increasingly dominated by newer therapies.
We are off to an excellent start in 2026,” said Robert A. Michael, Chief Executive Officer of AbbVie.
Our results exceed our expectations across our diverse portfolio, and we are raising our full-year guidance as a result of our strong operational performance.
Robert A. Michael, Chief Executive Officer of AbbVie
Learn More: AstraZeneca Q1 2026 Results: Strong 8% Growth and Clinical Breakthroughs
Immunology and Neuroscience Lead the Way
The immunology portfolio remains the crown jewel of AbbVie’s growth strategy. Skyrizi and Rinvoq combined for over $6.6 billion in sales this quarter, effectively mitigating the revenue loss from Humira biosimilars.
- Skyrizi: Global net revenues were $4.5 billion, a staggering 31% increase.
- Rinvoq: Global net revenues were $2.1 billion, up 23%.
- Humira: Experienced a 39% decline, generating $688 million as it continues to face erosion from biosimilar competition.
In the neuroscience segment, revenues climbed 24.3% to $2.9 billion. This was bolstered by strong demand for Vraylar and the migraine portfolio, including Ubrelvy, which saw a 41.4% revenue jump.
Clinical Pipeline Updates and Data
Beyond the financial metrics, the AbbVie First Quarter 2026 Financial Results highlighted significant progress in the company’s R&D pipeline. The following tables summarize key clinical milestones achieved during the first quarter.
Key Clinical Trial Results Q1 2026
| Treatment | Condition | Phase | Result / Status |
| Venclexta + Acalabrutinib | Chronic Lymphocytic Leukemia (CLL) | Phase 3 (AMPLIFY) | Positive topline data; first all-oral, fixed-duration regimen approved. |
| ABBV-295 | Obesity | Phase 1 | Showed clinically meaningful body weight reduction at weeks 12-13. |
| Rinvoq | Vitiligo & Alopecia Areata (AA) | Phase 3 | Demonstrated significant efficacy; regulatory submissions ongoing. |
| Skyrizi | Crohn’s Disease | Phase 3 | Subcutaneous induction therapy submitted for FDA approval. |
Learn More: Johnson & Johnson Q1 2026 Results: Financial Growth and Pipeline Breakthroughs
Portfolio Revenue Breakdown (Q1 2026)
| Portfolio Segment | Q1 2026 Revenue ($B) | Operational Growth (YoY %) |
| Immunology | $7.3 | +15.9% |
| Neuroscience | $2.9 | +24.3% |
| Oncology | $1.6 | -3.0% |
| Aesthetics | $1.2 | +5.1% |
FDA Announces AstraZeneca Truqap Prostate Cancer Approval for PTEN-Deficient Patients
US Food and Drug Administration has approved AstraZeneca's Truqap (capivasertib) combination therapy as the first and only targeted treatment for adult patients suffering from PTEN-deficient […]
Johnson & Johnson TALVEY Multiple Myeloma Treatment Shows Unprecedented Phase 3 MonumenTAL-3 Efficacy
Johnson & Johnson announced positive Phase 3 MonumenTAL-3 trial data demonstrating that a TALVEY-based bispecific combination significantly reduces the risk of progression or death in […]
Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected. […]
Future Guidance and Market Outlook
Based on the strong momentum seen in the AbbVie First Quarter 2026 Financial Results, the company has raised its full-year 2026 adjusted diluted EPS guidance range to $14.08 – $14.28. This update accounts for an unfavorable impact of $0.41 per share related to acquired IPR&D and milestones expense incurred year-to-date.
AbbVie’s management remains confident in its long-term outlook, particularly as it expands into new therapeutic areas like obesity with the ABBV-295 program. You can follow real-time market reactions and analysis on Seeking Alpha.
